172 related articles for article (PubMed ID: 25750636)
1. Promoter methylation status of Ras-association domain family members in pheochromocytoma.
Richter AM; Zimmermann T; Haag T; Walesch SK; Dammann RH
Front Endocrinol (Lausanne); 2015; 6():21. PubMed ID: 25750636
[TBL] [Abstract][Full Text] [Related]
2. The RASSF gene family members RASSF5, RASSF6 and RASSF7 show frequent DNA methylation in neuroblastoma.
Djos A; Martinsson T; Kogner P; Carén H
Mol Cancer; 2012 Jun; 11():40. PubMed ID: 22695170
[TBL] [Abstract][Full Text] [Related]
3. Aberrant Promoter Hypermethylation of RASSF Family Members in Merkel Cell Carcinoma.
Richter AM; Haag T; Walesch S; Herrmann-Trost P; Marsch WC; Kutzner H; Helmbold P; Dammann RH
Cancers (Basel); 2013 Nov; 5(4):1566-76. PubMed ID: 24252868
[TBL] [Abstract][Full Text] [Related]
4. Decreased expression and frequent promoter hypermethylation of RASSF2 and RASSF6 correlate with malignant progression and poor prognosis of gastric cardia adenocarcinoma.
Guo W; Dong Z; Guo Y; Shen S; Guo X; Kuang G; Yang Z
Mol Carcinog; 2016 Nov; 55(11):1655-1666. PubMed ID: 26456015
[TBL] [Abstract][Full Text] [Related]
5. Aberrant Promoter Methylation of the Tumour Suppressor RASSF10 and Its Growth Inhibitory Function in Breast Cancer.
Richter AM; Walesch SK; Dammann RH
Cancers (Basel); 2016 Feb; 8(3):. PubMed ID: 26927176
[TBL] [Abstract][Full Text] [Related]
6. Frequent epigenetic inactivation of RASSF2 in thyroid cancer and functional consequences.
Schagdarsurengin U; Richter AM; Hornung J; Lange C; Steinmann K; Dammann RH
Mol Cancer; 2010 Sep; 9():264. PubMed ID: 20920251
[TBL] [Abstract][Full Text] [Related]
7. The RASSF proteins in cancer; from epigenetic silencing to functional characterization.
Richter AM; Pfeifer GP; Dammann RH
Biochim Biophys Acta; 2009 Dec; 1796(2):114-28. PubMed ID: 19344752
[TBL] [Abstract][Full Text] [Related]
8. The novel RASSF6 and RASSF10 candidate tumour suppressor genes are frequently epigenetically inactivated in childhood leukaemias.
Hesson LB; Dunwell TL; Cooper WN; Catchpoole D; Brini AT; Chiaramonte R; Griffiths M; Chalmers AD; Maher ER; Latif F
Mol Cancer; 2009 Jul; 8():42. PubMed ID: 19570220
[TBL] [Abstract][Full Text] [Related]
9. N-terminal RASSF family: RASSF7-RASSF10.
Underhill-Day N; Hill V; Latif F
Epigenetics; 2011 Mar; 6(3):284-92. PubMed ID: 21116130
[TBL] [Abstract][Full Text] [Related]
10. Frequent epigenetic inactivation of RASSF10 in thyroid cancer.
Schagdarsurengin U; Richter AM; Wöhler C; Dammann RH
Epigenetics; 2009 Nov; 4(8):571-6. PubMed ID: 19934646
[TBL] [Abstract][Full Text] [Related]
11. Aberrant methylation of RASSF4/AD037 in nasopharyngeal carcinoma.
Chow LS; Lo KW; Kwong J; Wong AY; Huang DP
Oncol Rep; 2004 Oct; 12(4):781-7. PubMed ID: 15375500
[TBL] [Abstract][Full Text] [Related]
12. Promoter Hypermethylation of Genes Encoding for RASSF/Hippo Pathway Members Reveals Specific Alteration Pattern in Diffuse Gliomas.
Levallet G; Creveuil C; Bekaert L; Péres E; Planchard G; Lecot-Cotigny S; Guillamo JS; Emery E; Zalcman G; Lechapt-Zalcman E
J Mol Diagn; 2019 Jul; 21(4):695-704. PubMed ID: 31055025
[TBL] [Abstract][Full Text] [Related]
13. KIBRA gene methylation is associated with unfavorable biological prognostic parameters in chronic lymphocytic leukemia.
Shinawi T; Hill V; Dagklis A; Baliakas P; Stamatopoulos K; Agathanggelou A; Stankovic T; Maher ER; Ghia P; Latif F
Epigenetics; 2012 Mar; 7(3):211-5. PubMed ID: 22430796
[TBL] [Abstract][Full Text] [Related]
14. RASSF10 promoter hypermethylation is frequent in malignant melanoma of the skin but uncommon in nevus cell nevi.
Helmbold P; Richter AM; Walesch S; Skorokhod A; Marsch WCh; Enk A; Dammann RH
J Invest Dermatol; 2012 Mar; 132(3 Pt 1):687-94. PubMed ID: 22113481
[TBL] [Abstract][Full Text] [Related]
15. Genetic analyses of apparently sporadic pheochromocytomas: the Rotterdam experience.
Korpershoek E; Van Nederveen FH; Dannenberg H; Petri BJ; Komminoth P; Perren A; Lenders JW; Verhofstad AA; De Herder WW; De Krijger RR; Dinjens WN
Ann N Y Acad Sci; 2006 Aug; 1073():138-48. PubMed ID: 17102080
[TBL] [Abstract][Full Text] [Related]
16. RASSF4/AD037 is a potential ras effector/tumor suppressor of the RASSF family.
Eckfeld K; Hesson L; Vos MD; Bieche I; Latif F; Clark GJ
Cancer Res; 2004 Dec; 64(23):8688-93. PubMed ID: 15574778
[TBL] [Abstract][Full Text] [Related]
17. DNA hypermethylation of tumor suppressor genes RASSF6 and RASSF10 as independent prognostic factors in adult acute lymphoblastic leukemia.
Younesian S; Shahkarami S; Ghaffari P; Alizadeh S; Mehrasa R; Ghavamzadeh A; Ghaffari SH
Leuk Res; 2017 Oct; 61():33-38. PubMed ID: 28869817
[TBL] [Abstract][Full Text] [Related]
18. RASSF6 is a novel member of the RASSF family of tumor suppressors.
Allen NP; Donninger H; Vos MD; Eckfeld K; Hesson L; Gordon L; Birrer MJ; Latif F; Clark GJ
Oncogene; 2007 Sep; 26(42):6203-11. PubMed ID: 17404571
[TBL] [Abstract][Full Text] [Related]
19. RASSF6 exhibits promoter hypermethylation in metastatic melanoma and inhibits invasion in melanoma cells.
Mezzanotte JJ; Hill V; Schmidt ML; Shinawi T; Tommasi S; Krex D; Schackert G; Pfeifer GP; Latif F; Clark GJ
Epigenetics; 2014 Nov; 9(11):1496-503. PubMed ID: 25482183
[TBL] [Abstract][Full Text] [Related]
20. High frequency of promoter hypermethylation of RASSF1A and p16 and its relationship to aflatoxin B1-DNA adduct levels in human hepatocellular carcinoma.
Zhang YJ; Ahsan H; Chen Y; Lunn RM; Wang LY; Chen SY; Lee PH; Chen CJ; Santella RM
Mol Carcinog; 2002 Oct; 35(2):85-92. PubMed ID: 12325038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
